Sanofi Adr Stock Performance
| SNY Stock | USD 50.74 1.37 2.77% |
The entity has a beta of 0.25, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Sanofi ADR's returns are expected to increase less than the market. However, during the bear market, the loss of holding Sanofi ADR is expected to be smaller as well. At this point, Sanofi ADR has a negative expected return of -0.0779%. Please make sure to validate Sanofi ADR's treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Sanofi ADR performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Sanofi ADR has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Sanofi ADR is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 12.7 B |
Sanofi |
Sanofi ADR Relative Risk vs. Return Landscape
If you would invest 5,366 in Sanofi ADR on October 20, 2024 and sell it today you would lose (292.00) from holding Sanofi ADR or give up 5.44% of portfolio value over 90 days. Sanofi ADR is generating negative expected returns assuming volatility of 1.5874% on return distribution over 90 days investment horizon. In other words, 14% of stocks are less volatile than Sanofi, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Sanofi ADR Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sanofi ADR's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sanofi ADR, and traders can use it to determine the average amount a Sanofi ADR's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0491
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SNY |
Estimated Market Risk
| 1.59 actual daily | 14 86% of assets are more volatile |
Expected Return
| -0.08 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sanofi ADR is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sanofi ADR by adding Sanofi ADR to a well-diversified portfolio.
Sanofi ADR Fundamentals Growth
Sanofi Stock prices reflect investors' perceptions of the future prospects and financial health of Sanofi ADR, and Sanofi ADR fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sanofi Stock performance.
| Return On Equity | 0.0582 | ||||
| Return On Asset | 0.0416 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 141.27 B | ||||
| Shares Outstanding | 2.51 B | ||||
| Price To Earning | 7.78 X | ||||
| Price To Book | 1.65 X | ||||
| Price To Sales | 2.63 X | ||||
| Revenue | 46.03 B | ||||
| EBITDA | 12 B | ||||
| Cash And Equivalents | 6.9 B | ||||
| Cash Per Share | 2.76 X | ||||
| Total Debt | 18.42 B | ||||
| Debt To Equity | 0.30 % | ||||
| Book Value Per Share | 58.10 X | ||||
| Cash Flow From Operations | 10.26 B | ||||
| Earnings Per Share | 1.85 X | ||||
| Total Asset | 126.46 B | ||||
| Retained Earnings | 67.5 B | ||||
| Current Asset | 24.93 B | ||||
| Current Liabilities | 16.82 B | ||||
About Sanofi ADR Performance
Evaluating Sanofi ADR's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Sanofi ADR has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sanofi ADR has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. Sanofi was founded in 1973 and is headquartered in Paris, France. Sanofi-Aventis operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 95442 people.Things to note about Sanofi ADR performance evaluation
Checking the ongoing alerts about Sanofi ADR for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sanofi ADR help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sanofi ADR generated a negative expected return over the last 90 days | |
| Sanofi ADR has a strong financial position based on the latest SEC filings |
- Analyzing Sanofi ADR's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sanofi ADR's stock is overvalued or undervalued compared to its peers.
- Examining Sanofi ADR's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sanofi ADR's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sanofi ADR's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sanofi ADR's stock. These opinions can provide insight into Sanofi ADR's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Sanofi Stock Analysis
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.